Skip to main content
SpringerLink
Log in

Targeted and Immune Therapy for Periocular and Orbital Malignancies

  • Chapter
  • First Online:
Orbit and Oculoplastics

Part of the book series: Current Practices in Ophthalmology ((CUPROP))

  • 368 Accesses

Abstract

The use of targeted therapy and immune checkpoint inhibitors have significantly contributed to the treatment of patients with locally advanced, unresectable metastatic periocular cancers. Sonic Hedgehog inhibitors are used to treat locally advanced or metastatic periocular basal cell carcinoma and have been found to enable a less-extensive definitive surgery. Epidermal growth factor receptor antagonists have been used to treat patients with locally advanced periocular squamous cell carcinoma with a significant reduction in tumor size and improvement in quality of life. BRAF inhibitors, with or without concurrent MEK inhibitors, have been used to treat patients with cutaneous melanoma metastatic to the orbit. Immune checkpoint inhibitors have been used to treat patients with orbital metastasis from cutaneous melanoma and patients with eyelid and conjunctival metastatic melanoma. The authors of the chapter have also observed preliminary positive response in locally advanced recurrent periocular squamous cell carcinoma treated with immune checkpoint inhibitors. These promising results for treatment of both locally advanced and metastatic periocular tumors should encourage ophthalmologists and oculoplastic surgeons to implement these treatments in appropriate cases as described in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. US-FDA. FDA labeling information—ERIVEDGE. FDA website. 2012. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf.

  2. Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70(1):60–9.

    Article  CAS  PubMed  Google Scholar 

  4. Basset-Seguin N, Hauschild A, Grob JJ, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015;16(6):729–36.

    Article  CAS  PubMed  Google Scholar 

  5. Jacobsen AA, Aldahan AS, Hughes OB, et al. Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: a systematic review and pooled analysis of interventional studies. JAMA Dermatol. 2016;152(7):816–24.

    Article  PubMed  Google Scholar 

  6. Ozgur OK, Yin V, Chou E, et al. Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome. Am J Ophthalmol. 2015;160(2):220–227.e222.

    Article  CAS  PubMed  Google Scholar 

  7. Tang JY, Ally MS, Chanana AM, et al. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(12):1720–31.

    Article  CAS  PubMed  Google Scholar 

  8. Yin VT, Esmaeli B. Targeting the hedgehog pathway for locally advanced and metastatic basal cell carcinoma. Curr Pharm Des. 2017;23(4):655–9.

    Article  PubMed  CAS  Google Scholar 

  9. Demirci H, Worden F, Nelson CC, et al. Efficacy of vismodegib (erivedge) for basal cell carcinoma involving the orbit and periocular area. Ophthal Plast Reconstr Surg. 2015;31(6):463–6.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Wong KY, Fife K, Lear JT, et al. Vismodegib for locally advanced periocular and orbital basal cell carcinoma: a review of 15 consecutive cases. Plast Reconstr Surg Glob Open. 2017;5(7):e1424.

    Article  PubMed  PubMed Central  Google Scholar 

  11. US-FDA. FDA labeling information—ODOMZO. FDA website. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266s000lbl.pdf.

  12. Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018;32(3):372–81.

    Article  CAS  PubMed  Google Scholar 

  13. Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma. Arch Dermatol. 2012;148(11):1324–5.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. US_Department_of_Health_Human_Services. Common terminology criteria for adverse events (CTCAE) version 4.03, 2010. Bethesda, MD: National Institutes of Health, National Cancer Institute; 2016.

    Google Scholar 

  16. Ally MS, Tang JY, Lindgren J, et al. Effect of calcium channel blockade on vismodegib-induced muscle cramps. JAMA Dermatol. 2015;151(10):1132–4.

    Article  PubMed  Google Scholar 

  17. Moreira J, Tobias A, O’Brien MP, Agulnik M. Targeted therapy in head and neck cancer: an update on current clinical developments in epidermal growth factor receptor-targeted therapy and immunotherapies. Drugs. 2017;77(8):843–57.

    Article  CAS  PubMed  Google Scholar 

  18. Shepler TR, Prieto VG, Diba R, et al. Expression of the epidermal growth factor receptor in conjunctival squamous cell carcinoma. Ophthal Plast Reconstr Surg. 2006;22(2):113–5.

    Article  PubMed  Google Scholar 

  19. US-FDA. FDA labeling information—ERBITUX. FDA website. 2004. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125084s168lbl.pdf.

  20. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–8.

    Article  CAS  PubMed  Google Scholar 

  21. Acevedo-Henao CM, Valette G, Miglierini P, et al. Radiotherapy combined with cetuximab for locally advanced head and neck cancer: results and toxicity. Cancer Radiother. 2012;16(7):601–3.

    Article  CAS  PubMed  Google Scholar 

  22. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.

    Article  CAS  PubMed  Google Scholar 

  23. Knoedler M, Gauler TC, Gruenwald V, et al. Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie. Oncology. 2013;84(5):284–9.

    Article  CAS  PubMed  Google Scholar 

  24. Thomas F, Rochaix P, Benlyazid A, et al. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res. 2007;13(23):7086–92.

    Article  CAS  PubMed  Google Scholar 

  25. Herchenhorn D, Dias FL, Viegas CM, et al. Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2010;78(3):696–702.

    Article  CAS  PubMed  Google Scholar 

  26. Hainsworth JD, Spigel DR, Greco FA, et al. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium. Cancer J (Sudbury, Mass). 2011;17(5):267–72.

    Article  CAS  Google Scholar 

  27. Martins RG, Parvathaneni U, Bauman JE, et al. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol. 2013;31(11):1415–21.

    Article  CAS  PubMed  Google Scholar 

  28. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22(1):77–85.

    Article  CAS  PubMed  Google Scholar 

  29. El-Sawy T, Sabichi AL, Myers JN, et al. Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol. 2012;130(12):1608–11.

    Article  PubMed  Google Scholar 

  30. Saint-Jean A, Sainz de la Maza M, Morral M, et al. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases. Ophthalmology. 2012;119(9):1798–802.

    Article  PubMed  Google Scholar 

  31. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Cosgarea I, Ritter C, Becker JC, et al. Update on the clinical use of kinase inhibitors in melanoma. J Dtsch Dermatol Ges. 2017;15(9):887–93.

    PubMed  Google Scholar 

  33. US-FDA. FDA labeling information—ZELBORAF. FDA website. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s012lbl.pdf.

  34. US-FDA. FDA labeling information—TAFLINAR. FDA website. 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202806s002lbl.pdf.

  35. US-FDA. FDA labeling information—MEKINIST. FDA website. 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204114s001lbl.pdf.

  36. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Ascierto PA, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–60.

    Article  CAS  PubMed  Google Scholar 

  39. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–51.

    Article  CAS  PubMed  Google Scholar 

  41. Larsen AC, Dahl C, Dahmcke CM, et al. BRAF mutations in conjunctival melanoma: investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions. Acta Ophthalmol. 2016;94(5):463–70.

    Article  CAS  PubMed  Google Scholar 

  42. Griewank KG, Westekemper H, Murali R, et al. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res. 2013;19(12):3143–52.

    Article  CAS  PubMed  Google Scholar 

  43. Dagi Glass LR, Lawrence DP, Jakobiec FA, Freitag SK. Conjunctival melanoma responsive to combined systemic BRAF/MEK inhibitors. Ophthal Plast Reconstr Surg. 2017;33(5):e114–6.

    Article  PubMed  Google Scholar 

  44. Liu M, Yang X, Liu J, et al. Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials. Oncotarget. 2017;8(19):32258–69.

    PubMed  PubMed Central  Google Scholar 

  45. Peng L, Wang Y, Hong Y, et al. Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis. Oncotarget. 2017;8(47):83280–91.

    PubMed  PubMed Central  Google Scholar 

  46. Yin VT, Wiraszka TA, Tetzlaff M, et al. Cutaneous eyelid neoplasms as a toxicity of vemurafenib therapy. Ophthal Plast Reconstr Surg. 2015;31(4):e112–5.

    Article  PubMed  Google Scholar 

  47. US-FDA. FDA labeling information—OPDIVO. FDA website. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125554s024lbl.pdf.

  48. US-FDA. FDA labeling information—KEYTRUDA. FDA website. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s015lbl.pdf.

  49. US-FDA. FDA labeling information—YERVOY. FDA website. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s074lbl.pdf.

  50. US-FDA. FDA labeling information—BAVENCIO. FDA website. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf.

  51. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Barone A, Hazarika M, Theoret MR, et al. FDA approval summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanoma. Clin Cancer Res. 2017;23(19):5661–5.

    Article  CAS  PubMed  Google Scholar 

  54. Beaver JA, Theoret MR, Mushti S, et al. FDA approval of nivolumab for the first-line treatment of patients with BRAFV600 wild-type unresectable or metastatic melanoma. Clin Cancer Res. 2017;23(14):3479–83.

    Article  CAS  PubMed  Google Scholar 

  55. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Hazarika M, Chuk MK, Theoret MR, et al. U.S. FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab. Clin Cancer Res. 2017;23(14):3484–8.

    Article  CAS  PubMed  Google Scholar 

  57. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–17.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Ford J, Thuro BA, Thakar S, et al. Immune checkpoint inhibitors for treatment of metastatic melanoma of the orbit and ocular adnexa. Ophthal Plast Reconstr Surg. 2017;33(4):e82–5.

    Article  PubMed  Google Scholar 

  61. Emens LA, Ascierto PA, Darcy PK, et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017;81:116–29.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Oded Sagiv, Bashar Jaber & Bita Esmaeli

  2. St John Eye Hospital Group, Jerusalem, Israel

    Bashar Jaber

Authors
  1. Oded Sagiv
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bashar Jaber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bita Esmaeli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bita Esmaeli .

Editor information

Editors and Affiliations

  1. Mumbai Eye Plastic Surgery, Mumbai, Maharashtra, India

    Adit Gupta

  2. Mumbai Eye Plastic Surgery, Mumbai, Maharashtra, India

    Prerana Tahiliani

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sagiv, O., Jaber, B., Esmaeli, B. (2019). Targeted and Immune Therapy for Periocular and Orbital Malignancies. In: Gupta, A., Tahiliani, P. (eds) Orbit and Oculoplastics . Current Practices in Ophthalmology. Springer, Singapore. https://doi.org/10.1007/978-981-13-8538-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-8538-4_8

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-8537-7

  • Online ISBN: 978-981-13-8538-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation